)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Adverum Biotechnologies (ADVM) investor relations material
Adverum Biotechnologies Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary12 Nov, 2025
Executive summary
Entered into a merger agreement with Eli Lilly, including a tender offer and contingent value rights (CVRs) for shareholders, with the merger expected to close in Q4 2025.
Lead product candidate Ixo-vec advanced to Phase 3 trials for wet AMD, with full enrollment for ARTEMIS expected in Q4 2025 and top-line data in Q1 2027.
Substantial doubt exists regarding ability to continue as a going concern, with cash and equivalents insufficient to fund operations for 12 months without additional financing or merger completion.
Financial highlights
Cash, cash equivalents, and short-term investments totaled $26.1 million as of September 30, 2025, down from $125.7 million at December 31, 2024.
Net loss for Q3 2025 was $47.7 million, compared to $32.4 million in Q3 2024; net loss for the nine months ended September 30, 2025 was $143.9 million, up from $90.0 million in the prior year period.
Operating expenses increased to $48.0 million in Q3 2025 (from $35.4 million in Q3 2024), primarily due to higher R&D spending on Ixo-vec Phase 3 activities.
Cash used in operations for the nine months ended September 30, 2025 was $109.7 million.
Outlook and guidance
Cash, equivalents, and advances under the secured note with Lilly are expected to fund operations through the anticipated merger close.
If the merger is not completed, additional financing will be required; failure to secure funding may result in bankruptcy or liquidation.
ARTEMIS Phase 3 trial full enrollment expected in Q4 2025, with top-line data in Q1 2027; AQUARIUS Phase 3 trial initiation planned for Q4 2025.
Factors impacting Ixo-vec CVR payments
Post-merger termination liquidity plan
Ixo-vec manufacturing scale-up challenges
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Adverum Biotechnologies earnings date
Q4 202515 Apr, 2026
Next Adverum Biotechnologies earnings date
Q4 202515 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Adverum Biotechnologies Inc, originally known as Avalanche Biotechnologies Inc, is a clinical-stage gene therapy company based in Redwood City, California. Focused on addressing unmet medical needs, the company targets serious ocular and rare diseases, including wet age-related macular degeneration (wet AMD). It leverages its proprietary intravitreal (IVT) platform to develop durable, single-administration therapies intended to be delivered in physicians' offices. This approach aims to transform the standard of care for highly prevalent ocular diseases by eliminating the need for frequent ocular injections. The company is headquartered in Redwood City, California, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage